Aethlon Medical To Present at 2008 Southern California Investor Conference

SAN DIEGO--(Business Wire)--
Aethlon Medical, Inc. (OTCBB:AEMD) today announced that Chairman
and Chief Executive Officer, James A. Joyce, will present a company
overview at the California Stock Report's 2008 Southern California
Investor Conference being held tomorrow, September 3rd, at The Island
Hotel in Newport Beach, California. A live audio webcast of the
Aethlon Medical presentation, which is scheduled at 10:30 a.m. Pacific
Time, may be accessed via California Stock Report's website at
www.californiastocks.com. Listeners are encouraged to visit the
website at least 15 minutes prior to the start of the scheduled
presentation to register, download and install any necessary audio
software.

About Aethlon Medical

Aethlon Medical is the developer of the Hemopurifier(R), a
first-in-class medical device designed to treat infectious disease.
The Hemopurifier(R) provides real-time therapeutic filtration of
infectious viruses and immunosuppressive particles, and is positioned
to address the treatment of drug and vaccine resistant viruses.
Additionally, the device holds promise in cancer care, as research
studies have verified the Hemopurifier(R) is able to capture
immunosuppressive particles secreted by tumors. The Hemopurifier(R) is
designed to act both as a stand-alone therapeutic, and as an adjunct
treatment to enhance clinical benefit of established therapies.
Pre-clinical studies conducted by researchers representing leading
government and non-government health organizations both in the United
States and abroad have documented the effectiveness of the
Hemopurifier(R) in capturing from circulation the viruses that
constitute pandemic threats, including H5N1 Avian Influenza (bird
flu), and Dengue Hemorrhagic Fever (DHF) from circulation. The company
is conducting studies to support the use of the Hemopurifier(R) as a
broad-spectrum treatment countermeasure against bioterror threats,
including Smallpox, and Ebola, Marburg, and Lassa hemorrhagic fever.
Regulatory and commercialization initiatives in the United States are
presently focused on bioterror threats, while international
initiatives are directed toward naturally evolving pandemic threats,
and chronic infectious disease conditions including the Human
Immunodeficiency Virus (HIV) and Hepatitis-C (HCV). Aethlon
demonstrated the safety of the Hemopurifier(R) in a 24-treatment human
study at the Apollo Hospital in Delhi, India, and is currently
conducting further human studies at the Fortis Hospital, also located
in Delhi. The company has submitted an investigational device
exemption (IDE) to the U.S. Food and Drug Administration (FDA) to
advance the Hemopurifier(R) as a broad-spectrum treatment
countermeasure against category "A" bioterror threats. Additional
information regarding Aethlon Medical and its Hemopurifier(R)
technology is available online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and
involve risks and uncertainties. Such forward-looking statements
involve assumptions, known and unknown risks, uncertainties and other
factors which may cause the actual results, performance or
achievements of Aethlon Medical, Inc to be materially different from
any future results, performance, or achievements expressed or implied
by the forward-looking statements. Such potential risks and
uncertainties include, without limitation, the Company's ability to
raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to
obtain FDA and other regulatory approvals permitting the sale of its
products, the Company's ability to manufacture its products and
provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and
Exchange Commission filings.

Aethlon Medical, Inc.
Jim Frakes
Senior VP Finance
858.459.7800 x300
jfrakes@aethlonmedical.com
or
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

Copyright Business Wire 2008